04:07 AM EDT, 10/27/2025 (MT Newswires) -- Medtronic ( MDT ) said Sunday that its Symplicity Spyral renal denervation procedure "significantly" reduced blood pressure compared to patients treated with placebo surgery, according to the final results of a three-year clinical trial.

The 206 patients who underwent the procedure showed significantly greater reductions in both 24-hour ambulatory systolic blood pressure and office-based systolic blood pressure compared to 131 placebo patients, the company said.

In addition, no renal artery narrowing greater than 70% was observed in the group that underwent the procedure over three years, suggesting the safety of Symplicity Spyral, the company said.